
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen Inc. is advancing its innovative preclinical programs that focus on the modulation of the Wnt pathway, which has demonstrated the potential to stimulate retinal vessel regrowth and suppress pathological vessel growth. The company's exploration of the FZD4 lipoprotein receptor-related protein as a bi-specific antibody for targeting Wnt signaling in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) suggests a strong market position in ophthalmology. Overall, these clinical advancements, combined with a robust internal Wnt platform, provide a promising foundation for the company's future growth and value creation.
Bears say
Surrozen Inc. faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its developmental candidates to meet peak commercial revenue estimates, which could be influenced by market size and pricing dynamics. Additionally, the company reported a substantial net loss of $27.0 million, or $7.43 per diluted share, for the first quarter of fiscal year 2025, indicating ongoing financial strain. Lastly, challenges related to securing necessary capital resources to fund operations further compound the uncertainties surrounding continued program development and commercialization efforts.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares